Shares of Exelixis EXEL rose in after-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share decreased 46.15% over the past year to $0.14, which beat the estimate of $0.05.
Revenue of $270,052,000 rose by 12.38% from the same period last year, which beat the estimate of $262,140,000.
Looking Ahead
Exelixis hasn't issued any earnings guidance for the time being.
The upcoming fiscal year's revenue expected to be between $1,150,000,000 and $1,250,000,000.
How To Listen To The Conference Call
Date: Feb 10, 2021
Time: 05:00 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/xj465twv
Technicals
Company's 52-week high was at $27.80
Company's 52-week low was at $13.67
Price action over last quarter: Up 11.54%
Company Description
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule cabozantinib is indicated for the treatment of patients with metastatic medullary thyroid cancer (as Cometriq) and advanced renal cell carcinoma, or kidney cancer, and hepatocellular carcinoma, or liver cancer (as Cabometyx). Exelixis and partner Roche have also brought Cotellic to market for the treatment of melanoma.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
